Vectura Group
 | |
| Public (LSE: VEC) | |
| Industry | Pharmaceuticals |
| Founded | 1997 |
| Headquarters | Chippenham, UK |
Key people |
Bruno Angelici, Chairman James Ward-Lilley, (CEO) |
| Revenue | £72.0 million (2016)[1] |
| £(5.1) million (2016)[1] | |
| £5.0 million (2016)[1] | |
| Website | www.vectura.com |
Vectura Group plc (LSE: VEC) is a British-based pharmaceuticals business. It is based in Chippenham and is a constituent of the FTSE 250 Index.
History
The company was formed in 1997 as a start-up pharmaceuticals business.[2] In 1999 it acquired Co-ordinated Drug Development and the Centre for Drug Formulation Studies.[2] In 2004 it was listed on the Alternative Investment Market.[2] In 2007 it acquired Innovata plc, another developer of pulmonary products,[3] and then moved on the full list of the London Stock Exchange.[2] It acquired Activaero, a German manufacturer in the same sector, for £108 million in March 2014.[4] On 10 June 2016 Vectura completed a merger with Skyepharma; the merged company will continue to be known as Vectura.[5]
Operations
The Group is a developer of inhaled therapies for the treatment of respiratory diseases.[6]
References
- 1 2 3 "Annual Report 2015/16" (PDF). Vectura Group. Retrieved 24 November 2016.
- 1 2 3 4 "History". Vectura Group. Retrieved 3 August 2016.
- ↑ Vectura buys Innovata Guardian, 17 November 2006
- ↑ "UK's Vectura buys Activaero for £108 million". Pharma Times. 16 March 2014. Retrieved 20 June 2015.
- ↑ "Vectura and Skyepharma to merge in £441m deal". The Telegraph. 16 March 2016. Retrieved 11 June 2016.
- ↑ "Dr Karl Keegan to join Vectura Group". Manufacturing chemist. Retrieved 20 June 2015.
External links
|
This article is issued from Wikipedia - version of the 11/24/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.